Coherus BioSciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Coherus BioSciences, Inc. (a Delaware corporation) on November 12, 2014. The report documents corporate actions taken in connection with the closing of the Company's initial public offering (IPO) of common stock.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data disclosed relates to the capital raise:
- Shares Sold: 6,803,702 shares of common stock.
- Offering Price: $13.50 per share to the public.
- Underwriter Option: Included the purchase of 507,402 additional shares by underwriters pursuant to a partial exercise of their option.
Material Changes
The following material changes occurred on November 12, 2014:
- Corporate Governance: The Company filed an Amended and Restated Certificate of Incorporation and adopted Amended and Restated Bylaws with the Delaware Secretary of State.
- Capital Structure: The Company transitioned from a private to a public entity through the completion of its IPO.
Guidance, Outlook, and Risks
This filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors. The document focuses strictly on the legal and procedural completion of the IPO and the associated charter amendments. Investors should refer to the Registration Statement on Form S-1 (File No. 333-198936) for detailed risk factors and outlook.
Key Facts for Investor Verification
- Verify the total gross proceeds from the IPO by calculating the share count (6,803,702) multiplied by the price ($13.50).
- Confirm the exact terms of the underwriters' partial option exercise (507,402 shares) in the final prospectus.
- Review the attached Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) for changes to authorized share counts and governance rules.
- Consult the Form S-1 Registration Statement for comprehensive financial history and risk disclosures not included in this 8-K.